NXY-059: Review of Neuroprotective Potential for Acute Stroke

@article{Fong2006NXY059RO,
  title={NXY-059: Review of Neuroprotective Potential for Acute Stroke},
  author={Jeffrey J. Fong and Denise H. Rhoney},
  journal={Annals of Pharmacotherapy},
  year={2006},
  volume={40},
  pages={461 - 471}
}
Objective: To review available literature on the pharmacology, pharmacokinetics, efficacy, and tolerability of NXY-059, an Investigational agent with a potential role in the treatment of acute stroke. Data Sources: Information was obtained from a MEDLINE search (1966–February 2006) of English-language literature utilizing the following search terms: NXY-059, cerovive, nitrones, neuroprotection, free radical trapper, and secondary neurologic injury. Study Selection and Data Extraction: Data from… Expand
Neuroprotection: challenges and opportunities.
TLDR
Both the critical problems and potential solutions are reviewed, emphasizing recent experimental and clinical work, regarding future clinical trials of neuroprotective agents. Expand
Challenges and Opportunities
TLDR
Both the critical problems and potential solutions are reviewed, emphasizing recent experimental and clinical work, emphasized in ArchNeurol. Expand
Pyruvate protects against experimental stroke via an anti-inflammatory mechanism
TLDR
Pyruvates protects against ischemia possibly by blocking inflammation, but lactate itself does not appear to explain pyruvate's anti-inflammatory properties. Expand
A new approach for the investigation of reperfusion-related brain injury.
TLDR
This new model is ideal for studying ischaemia/reperfusion-induced vascular injury and secondary brain damage and offers a unique opportunity to evaluate free radical-based neurovascular protective strategies. Expand
Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.
TLDR
The current understanding of the mechanisms of HIV-induced neurological disease is summarized, and translation of this basic research into potential clinical applications is emphasized. Expand
CholesteroNitrones for Stroke.
TLDR
The compound significantly increased cell viability, induced neuroprotection following ischemic reperfusion, and decreased neurological deficit scores in treated animals, supporting the next preclinical studies as a potential agent for the treatment of stroke. Expand
Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.
TLDR
The aim of this review is to update evidence on phagocyte-related oxidative stress, focusing on the role of NOX2 as a potential therapeutic target to reduce ROS-related cerebral injury after stroke. Expand
The proposed role of optical sensing in translational stroke research
TLDR
The proposed sequential intra‐arterial therapy for stroke (SITS) relies on the development of novel intra-arterial treatments of ischemic brain injury in the magnetic resonance imaging environment, and could greatly benefit from the advances in optical technologies. Expand
Nitrones as Potent Anticancer Therapeutics
TLDR
It is found that the PBN-analogue, OKN-007 (OKlahoma Nitrone), is able to inhibit the growth of human HCC cells and the mechanism-of-action of these nitrones as anticancer agents seems to be associated with the inhibition of cell growth and angiogenesis, as well as the induction of apoptosis. Expand
Drugs for stroke: action of nitrone (Z)-N-(2-bromo-5-hydroxy-4-methoxybenzylidene)-2-methylpropan-2-amine oxide on rat cortical neurons in culture subjected to oxygen-glucose-deprivation.
TLDR
Results show that nitrone RP6 protects cells against ischemia injury produced during the reoxygenation, and could be a potential drug for the ictus therapy. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 81 REFERENCES
Tolerability of NXY-059 at Higher Target Concentrations in Patients With Acute Stroke
TLDR
NXY-059 was well tolerated in patients with an acute stroke at and above concentrations shown to be neuroprotective in an animal model when initiated 4 hours after onset of permanent focal ischemia. Expand
Tolerability and Pharmacokinetics of the Nitrone NXY-059 in Patients With Acute Stroke
TLDR
NXY-059 was well tolerated in patients with an acute stroke, and the testing of higher doses in future trials may be justified. Expand
NXY-059 for acute ischemic stroke.
TLDR
The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Expand
Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059.
TLDR
NXY-059 may be the first compound to be examined in stroke patients using drug exposure and time to treatment that have been shown to be effective in animal models of stroke. Expand
Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures
TLDR
The overview of the behavioural effects and these new histological findings suggest that NXY-059 was by far the most effective neuroprotective agent of the three examined. Expand
NXY-059, a Free Radical–Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate Species
TLDR
This novel drug has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species, and these findings provide considerable encouragement for the clinical development of NXY-059. Expand
Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores
TLDR
This study shows that NXY-059 is neuroprotective over a wide range if administered early following an embolic stroke and can be administered in combination with tenecteplase to provide additional behavioral improvement at extended delays following embolization. Expand
Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects.
TLDR
It appears that NXY-059 is well tolerated and has a highly predictable pharmacokinetic profile, and clearance of N XY-059 was significantly correlated to creatinine clearance in the elderly. Expand
Neuroprotective Effects of a Novel Nitrone, NXY-059, after Transient Focal Cerebral Ischemia in the Rat
TLDR
Studies of the transfer constant of [14C]NXY-059 showed that, in contrast to PBN, this more soluble nitrone penetrates the blood-brain barrier less extensively, suggesting that the delayed events leading to infarction may be influenced by reactions occurring at the blood–endothelial interface. Expand
Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke
TLDR
Non-renal elimination of N XY-059 appeared to be insignificant even in subjects with low renal capacity, and patients with renal impairment should have their dose of NXY-059 adjusted for renal function, conveniently assessed from serum creatinine. Expand
...
1
2
3
4
5
...